Phase II Study of Daily Adaptive Radiotherapy for Submandibular Gland-sparing in Head and Neck Cancer

This is a randomized, single centre, single blinded prospective study comparing the standard of care imaging guided radiation therapy and daily adaptive radiotherapy (ART) for submandibular gland-sparing in head and neck cancer

Trial Details

NCT ID
NCT07348887
Phase
NA
Sponsor
University Health Network, Toronto
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Daily adaptive radiation therapy
  • Image guided radiation therapy
Locations (sample)
  • Toronto, Ontario, Canada|43.65333,-79.38389

Key Eligibility Criteria

  • Age ≥ 18 years
  • Histologically proven Squamous Cell carcinoma of head and neck
  • Bilateral neck being treated
  • At least one level 1b not being treated electively and with no target structure, other than elective level II/III, \<1cm to spared SMG

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →